Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by inthnoon Aug 19, 2023 12:06pm
285 Views
Post# 35596286

MBC phase 3

MBC phase 3
Hopefully Panc should be settled soon and favorably.... It will be interesting to see if we try it alone or partner.
Just curious if anyone has concern with the new guidance for the mbc phase 3 trial which is now 550 patients as compared to the original 400 patients with a spa in the original December 5th 2017 press release from onc.
One would think that with all they learned from the aware1 , bracelet and new biomarkers that I thought it was supposed to reduce trial time, derisk the trial and lower the patient numbers especially with the use of the biomarkers...
Just curious on thoughts as I do find it confusing that we will now basically be running the same trial but with a much larger number of patients.
Thanks for the thoughts
<< Previous
Bullboard Posts
Next >>